Epidemiology of Alcohol Consumption and Societal Burden of Alcoholism and Alcoholic Liver Disease

Axley, Page; Richardson, Crit Taylor; Singal, Ashwani K.

doi:10.1016/j.cld.2018.09.011

Cited by 150 publications

(122 citation statements)

References 78 publications

Supporting

Mentioning

101

Contrasting

Unclassified

Order By: Relevance

“…These findings are in agreement with reports from different parts of the world, emphasizing the increasing burden of ALD in those populations. ( 3,31‐33 )…”

Section: Discussionmentioning

confidence: 99%

Nonalcoholic Fatty Liver Disease and Alcoholic Liver Disease are Major Drivers of Liver Mortality in the United States

et al. 2020

View full text Add to dashboard Cite

In the United States, chronic viral hepatitis B and C (CHB and CHC), nonalcoholic fatty liver disease (NAFLD), and alcohol-related liver disease (ALD) are the main causes of liver deaths attributable to hepatocellular carcinoma (HCC) and cirrhosis. Our aim was to assess the changes in the rates of mortality and years of potential life lost (YLL) for HCC and cirrhosis due to different liver diseases. We used multiple-cause mortality data (2007-2017) from the National Center for Health Statistics. Annual percentage change (APC) in age-standardized death rate per 100,000 (ASDR) and age-standardized years of life lost per 100,000 (ASYLLR) were calculated. In the United States in 2017, there were 2,797,265 deaths with 73,424 liver deaths, contributing to 1,467,742 of YLL. Of the liver deaths, HCC was noted in 12,169 (16.6%) and cirrhosis in 60,111 (82.0%). CHC was responsible for 50.4% of HCC deaths; NAFLD, 35.4%; HBV, 6.0%; ALD, 5.4%; and others, 2.8%. NAFLD was responsible for 48.9% of cirrhosis deaths; ALD, 34.7%; CHC, 12.3%; CHB, 0.9%; and others, 3.2%. Between 2007 and 2017, the increase in ASDR for HCC due to ALD and NAFLD accelerated after 2014 (APC, 11.38% and 6.55%, respectively) whereas CHC stabilized (APC, 0.63%; P = 0.272) after 2011. The increase in ASYLLR of HCC escalated after 2014 for ALD and NAFLD (APC, 12.12% and 6.15%, respectively) and leveled out for CHC after 2012 (APC, −1.05%; P = 0.056). Furthermore, the highest annual increase in ASDR and ASYLLR for cirrhosis was due to ALD (APC, 3.24% and 3.34%, respectively) followed by NAFLD (APC, 1.23% and 0.49%, respectively). Conclusion: Over the past decade, ASDR and ASYLLR due to ALD and NAFLD have been increasing in the United States. The rising burden of HCC and cirrhosis are primarily driven by NAFLD and ALD. (Hepatology Communications 2020;4:890-903).

show abstract

“…These findings are in agreement with reports from different parts of the world, emphasizing the increasing burden of ALD in those populations. ( 3,31‐33 )…”

Section: Discussionmentioning

confidence: 99%

Nonalcoholic Fatty Liver Disease and Alcoholic Liver Disease are Major Drivers of Liver Mortality in the United States

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Dodatkowo fakt, że patologiczne zmiany wątrobowe zachodzą bezobjawowo utrudnia wczesną diagnozę takich jednostek chorobowych [1]. Za zwiększającą się liczbę przypadków zachorowalności na niewydolność wątroby w Europie odpowiada głównie marskość (zwłóknienie) wątroby oraz rak wątrobowokomórkowy, zaś do wzrostu częstości występowania marskości wątroby przyczynia się rosnąca na przestrzeni lat konsumpcja alkoholu [2,3].…”

Section: Wprowadzenieunclassified

Kliniczne metody wspomagania niewydolnej wątroby

Ciezkowska

Pluta

2019

Postepy Biochem

View full text Add to dashboard Cite

Choroby wątroby prowadzące do jej niewydolności są jedną z najczęstszych przyczyn zgonów na całym świecie. Jak dotąd jedynym skutecznym sposobem leczeniem ostrej niewydolności wątroby jest jej przeszczep. Niestety niedobór odpowiednich dawców stanowi główne ograniczenie tej terapii. Z tego powodu naukowcy stale szukają alternatywnych rozwiązań dla transplantacji tego organu. Najbardziej obiecujące są systemy wspomagania wątroby i przeszczep komórkowy. Bez wątpienia hepatocyty są najlepszym źródłem komórek do zastosowania w terapiach wątrobowozastępczych. Jednakże izolowane ludzkie hepatocyty bardzo szybko odróżnicowują się i tracą swoje funkcje. Dlatego stale poszukuje się nowych źródeł komórek, które mogłyby zastąpić hepatocyty. Obecnie panuje pogląd, że aby pomóc pacjentom w walce z chorobami wątroby, potrzeba interdyscyplinarnego podejścia do rozwiązania tego problemu.

show abstract

“…Alcoholic liver disease (ALD), which is caused by chronic or acute alcohol overuse, ranges from alcoholic fatty liver, alcoholic steatohepatitis, and fibrosis to cirrhosis (Axley et al, 2019). ALD threatens human health.…”

Section: Introductionmentioning

confidence: 99%

“…ALD threatens human health. "In 2016, worldwide alcohol-attributable mortality was 38.8 per 100,000 people and 1,759 disability-adjusted life-years (DALYs) per 100,000 people" (Teschke, 2018;Axley et al, 2019). The underlying molecular mechanisms of ALD are associated with the hepatotoxicity of alcohol and its metabolites, oxidative stress and lipid peroxidation, cell apoptosis and autophagy, and other factors (Kong et al, 2019).…”

Section: Introductionmentioning

confidence: 99%

P-Hydroxyacetophenone Ameliorates Alcohol-Induced Steatosis and Oxidative Stress via the NF-κB Signaling Pathway in Zebrafish and Hepatocytes

et al. 2020

View full text Add to dashboard Cite

Epidemiology of Alcohol Consumption and Societal Burden of Alcoholism and Alcoholic Liver Disease

Cited by 150 publications

References 78 publications

Nonalcoholic Fatty Liver Disease and Alcoholic Liver Disease are Major Drivers of Liver Mortality in the United States

Nonalcoholic Fatty Liver Disease and Alcoholic Liver Disease are Major Drivers of Liver Mortality in the United States

Kliniczne metody wspomagania niewydolnej wątroby

P-Hydroxyacetophenone Ameliorates Alcohol-Induced Steatosis and Oxidative Stress via the NF-κB Signaling Pathway in Zebrafish and Hepatocytes

Contact Info

Product

Resources

About